Emergent BioSolutions | EBS - Debt


Emergent BioSolutions reported $903.2M in Debt for its fiscal quarter ending in June of 2023.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amarin USD 0 0 Mar/2025
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Exelixis USD 176.46M 3.38M Sep/2025
Glaxosmithkline GBP 17.75B 396M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Lonza CHF 4.71B 915M Dec/2024
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 734M 7M Sep/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
Pacira USD 372.19M 4.53M Dec/2025
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 2.71B 2.42B Dec/2025
Sanofi EUR 20.33B 1.43B Dec/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Xoma USD 120.79M 3.27M Jun/2024